Nkarta, Inc. Operating Lease, Right-of-Use Asset, Amortization Expense
Nkarta, Inc. (NKTX) reported Operating Lease, Right-of-Use Asset, Amortization Expense of $1.11 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Cash Flow › Operating Activities
us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense · last filed 2026-08-10
- Nkarta, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2026-06-30 was $565.00K, a 23.90% increase year-over-year.
- Nkarta, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2026-03-31 was $544.00K, a 12.86% increase year-over-year.
- Nkarta, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-12-31 was $523.00K, a 6.77% decline year-over-year.
- Nkarta, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-09-30 was $490.00K, a 14.19% decline year-over-year.
- Nkarta, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2025 was $1.95M, a 14.65% decline from fiscal 2024.
- Nkarta, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2024 was $2.29M, a 2.88% increase from fiscal 2023.
- Nkarta, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2023 was $2.22M, a 43.53% decline from fiscal 2022.
- Nkarta, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2022 was $3.94M, a 972.21% increase from fiscal 2021.
| Period end | Operating Lease, Right-of-Use Asset, Amortization Expense 3 month | Operating Lease, Right-of-Use Asset, Amortization Expense 6 month | Operating Lease, Right-of-Use Asset, Amortization Expense 6 month as first filed | Operating Lease, Right-of-Use Asset, Amortization Expense 9 month | Operating Lease, Right-of-Use Asset, Amortization Expense 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $565.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $1.11M 10-Q · filed 2026-08-10 | $1.63M derived: sum of 3 quarters · filed 2026-08-10 | $2.12M derived: sum of 4 quarters · filed 2026-08-10 | |
| 2026-03-31 | $544.00K 10-Q · filed 2026-05-12 | $1.07M derived: sum of 2 quarters · filed 2026-05-12 | $1.56M derived: sum of 3 quarters · filed 2026-05-12 | $2.01M derived: sum of 4 quarters · filed 2026-08-10 | |
| 2025-12-31 | $523.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | $1.01M derived: sum of 2 quarters · filed 2026-03-25 | $1.47M derived: sum of 3 quarters · filed 2026-08-10 | $1.95M 10-K · filed 2026-03-25 | |
| 2025-09-30 | $490.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $946.00K derived: sum of 2 quarters · filed 2026-08-10 | $1.43M 10-Q · filed 2025-11-10 | $1.99M derived: sum of 4 quarters · filed 2026-08-10 | |
| 2025-06-30 | $456.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $938.00K 10-Q · filed 2026-08-10 | $1.50M derived: sum of 3 quarters · filed 2026-08-10 | $2.07M derived: sum of 4 quarters · filed 2026-08-10 | |
| 2025-03-31 | $482.00K 10-Q · filed 2026-05-12 | $1.04M derived: sum of 2 quarters · filed 2026-05-12 | $1.61M derived: sum of 3 quarters · filed 2026-05-12 | $2.18M derived: sum of 4 quarters · filed 2026-05-12 | |
| 2024-12-31 | $561.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | $1.13M derived: sum of 2 quarters · filed 2026-03-25 | $1.69M derived: sum of 3 quarters · filed 2026-03-25 | $2.29M 10-K · filed 2026-03-25 | |
| 2024-09-30 | $571.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $1.13M derived: sum of 2 quarters · filed 2025-11-10 | $1.73M 10-Q · filed 2025-11-10 | $2.29M derived: sum of 4 quarters · filed 2025-11-10 | |
| 2024-06-30 | $562.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $1.15M 10-Q · filed 2025-08-12 | $1.72M derived: sum of 3 quarters · filed 2025-08-12 | $2.28M derived: sum of 4 quarters · filed 2025-08-12 | |
| 2024-03-31 | $592.00K 10-Q · filed 2025-05-14 | $1.16M derived: sum of 2 quarters · filed 2025-05-14 | $1.71M derived: sum of 3 quarters · filed 2025-05-14 | $2.27M derived: sum of 4 quarters · filed 2025-05-14 | |
| 2023-12-31 | $569.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-26 | $1.12M derived: sum of 2 quarters · filed 2025-03-26 | $1.68M derived: sum of 3 quarters · filed 2025-03-26 | $2.22M 10-K · filed 2025-03-26 | |
| 2023-09-30 | $553.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $1.11M derived: sum of 2 quarters · filed 2024-11-07 | $1.65M 10-Q · filed 2024-11-07 | $2.32M derived: sum of 4 quarters · filed 2024-11-07 | |
| 2023-06-30 | $555.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $1.10M 10-Q · filed 2024-08-13 | $1.77M derived: sum of 3 quarters · filed 2024-08-13 | $3.02M derived: sum of 4 quarters · filed 2024-08-13 | |
| 2023-03-31 | $545.00K 10-Q · filed 2024-05-09 | $1.21M derived: sum of 2 quarters · filed 2024-05-09 | $2.46M derived: sum of 3 quarters · filed 2024-05-09 | $3.10M derived: sum of 4 quarters · filed 2024-05-09 | |
| 2022-12-31 | $666.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | $1.92M derived: sum of 2 quarters · filed 2024-03-21 | $2.56M derived: sum of 3 quarters · filed 2024-03-21 | $3.94M 10-K · filed 2024-03-21 | |
| 2022-09-30 | $1.25M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $1.89M derived: sum of 2 quarters · filed 2023-11-09 | $3.27M 10-Q · filed 2023-11-09 | $3.31M derived: sum of 4 quarters · filed 2023-11-09 | |
| 2022-06-30 | $639.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $2.02M 10-Q · filed 2023-08-10 | $2.06M derived: sum of 3 quarters · filed 2023-08-10 | $2.15M derived: sum of 4 quarters · filed 2023-08-10 | |
| 2022-03-31 | $1.38M 10-Q · filed 2023-05-11 | $1.42M derived: sum of 2 quarters · filed 2023-05-11 | $1.52M derived: sum of 3 quarters · filed 2023-05-11 | $1.61M derived: sum of 4 quarters · filed 2023-05-11 | |
| 2021-12-31 | $43.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | $136.00K derived: sum of 2 quarters · filed 2023-03-16 | $230.00K derived: sum of 3 quarters · filed 2023-03-16 | $367.00K 10-K · filed 2023-03-16 | |
| 2021-09-30 | $93.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $187.00K derived: sum of 2 quarters · filed 2022-11-09 | $324.00K 10-Q · filed 2022-11-09 | $366.00K derived: sum of 4 quarters · filed 2022-11-09 | |
| 2021-06-30 | $94.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $231.00K 10-Q · filed 2022-08-11 | $273.00K derived: sum of 3 quarters · filed 2022-08-11 | $315.00K derived: sum of 4 quarters · filed 2022-08-11 | |
| 2021-03-31 | $137.00K 10-Q · filed 2022-05-12 | $179.00K derived: sum of 2 quarters · filed 2022-05-12 | $221.00K derived: sum of 3 quarters · filed 2022-05-12 | $260.00K derived: sum of 4 quarters · filed 2022-05-12 | |
| 2020-12-31 | $42.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | $84.00K derived: sum of 2 quarters · filed 2022-03-17 | $123.00K derived: sum of 3 quarters · filed 2022-03-17 | $262.00K 10-K · filed 2022-03-17 | |
| 2020-09-30 | $42.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $81.00K derived: sum of 2 quarters · filed 2021-11-10 | $220.00K 10-Q · filed 2021-11-10 | $248.00K derived: sum of 4 quarters · filed 2021-11-10 | |
| 2020-06-30 | $39.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | $178.00K 10-Q · filed 2021-08-12 | $177.99K 10-Q · filed 2020-08-20 | $206.00K derived: sum of 3 quarters · filed 2021-08-12 | $174.74K derived: sum of 4 quarters · filed 2021-08-12 |
| 2020-03-31 | $139.00K 10-Q · filed 2021-05-13 | $167.00K derived: sum of 2 quarters · filed 2021-05-13 | $135.74K derived: sum of 3 quarters · filed 2021-05-13 | ||
| 2019-12-31 | $28.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-25 | -$3.26K derived: sum of 2 quarters · filed 2021-03-25 | $152.00K 10-K · filed 2021-03-25 | ||
| 2019-09-30 | -$31.26K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-12 | $124.00K 10-Q · filed 2020-11-12 | |||
| 2019-06-30 | $155.26K 10-Q · filed 2020-08-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| Foghorn Therapeutics Inc. (FHTX) | United States | $0.213B | -4.43 |
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B | |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |